Assets: small peptidomimetics
IPCure is building a portfolio of first-in-class, highly selective small-molecule peptidomimetics targeting individual caspases.
Our lead program addresses Caspase-2, a pivotal regulator of synaptic function and neurodegeneration.
Compounds
DiscoveryLead opt.PreclinicalIND-enabling
Caspase-2 selective inhibitors
Casp2i
Frontotemporal Dementia (FTD-Tau)
Advanced preclinical
Casp2i
Alzheimer’s Disease (AD)
Preclinical
Caspases platform
Casp4i
Inflammatory diseases
Exploratory
Research tools · On the market (RUO)
Casp2i™ Selective inhibitors
Research Use Only (RUO)
Available now
Casp2Sense™ Selective AMC-based Fluorogenic Substrates
Research Use Only (RUO)
Available now